Wegovy pill 4 mg introductory price expires

Novo Nordisk's discounted self-pay price for the 4 mg Wegovy tablet expired on August 31, 2026. Patients paying cash for that dose now see a published price of $199 a month, up from the $149 introductory rate the company had offered ^[1][2][3].

The change affects only the 4 mg pill strength. Novo Nordisk's pricing materials show self-pay patients continue to pay $149 a month for the 1.5 mg tablet, while the higher-strength 9 mg and 25 mg tablets are listed at $299 a month ^[2]. The company's own footnotes spelled out the timeline in advance: "4 mg offer only available until August 31, 2026, then $199 per month for 4 mg" ^[1]. A separate company statement about a new subscription program, issued in March 2026, repeated the same cutoff date, confirming the price change was planned rather than a surprise ^[3].

The 4 mg tablet price shift is separate from other Wegovy pricing changes taking effect around the same period. Novo Nordisk's injectable pen doses have their own limited-time offer: new patients get the 0.25 mg or 0.5 mg pen for $199 a month for the first two months through December 31, 2026, after which the price rises to $349 a month for most pen doses and $399 a month for the high-dose 7.2 mg pen ^[1][2]. Those pen prices are unrelated to the tablet price discussed here.

People with commercial insurance are not affected by this self-pay change. Novo Nordisk's savings card continues to offer eligible commercially insured patients the pill or pen for as little as $25 a month, capped at $100 in monthly savings, according to the company's cost and coverage page ^[1][2]. Medicare beneficiaries have a separate path: a federal Medicare GLP-1 Bridge program is set to offer eligible Part D enrollees any dose of the Wegovy pen or pill for $50 a month between July 1, 2026, and December 31, 2027, subject to CMS eligibility rules ^[1].

Separately, Novo Nordisk launched a subscription option on March 31, 2026, through telehealth partners including Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame expected to join later ^[3]. That subscription program applies to the 9 mg and 25 mg tablet doses and to pen doses, not the 4 mg tablet. Self-pay patients using the subscription can lock in lower monthly rates by committing to 3-, 6-, or 12-month terms, with savings advertised at up to $600 a year on the pill and up to $1,200 a year on the pen ^[3]. The company's announcement of that program also referenced the same August 31, 2026 end date for the 4 mg introductory price, so the two changes were coordinated on the same calendar ^[3].

Why it matters for patients

For people using the cash-pay 4 mg tablet without insurance or a subscription, the monthly out-of-pocket cost is now $50 higher than it was before September 2026 ^[1][2]. That is a 34% increase from $149 to $199 for that specific dose. People taking the 1.5 mg tablet are not affected by this particular change, since that dose has kept its $149 self-pay price ^[2]. Patients with commercial insurance or Medicare coverage under the GLP-1 Bridge program may not see any change at all, since those prices are set separately from the self-pay list price ^[1].

Anyone unsure which price applies to them should check with their pharmacy or Novo Nordisk's NovoCare program directly, since self-pay, insurance copay, Medicare, and subscription prices for Wegovy can differ substantially by dose and by how the prescription is filled ^[1][2][3].

What happens next

The Medicare GLP-1 Bridge program is scheduled to begin July 1, 2026, and run through December 31, 2027, offering eligible enrollees Wegovy pen and pill doses for $50 a month ^[1]. The two-month introductory pen offer for new patients is set to expire December 31, 2026, after which those doses rise to $349 or $399 a month ^[1][2]. It is not yet known from available sources whether Novo Nordisk plans further price changes to the 4 mg tablet or other doses beyond these dated milestones.